ERAS 2021: CHF Solutions to Host On-Demand Presentation on Management of Fluid Overload in Cardiac Surgery Patients

CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, will participate in the first ERAS Cardiac Society Virtual Conference, broadcasting Live from Methodist Hospital DeBakey Center in Houston, Texas on March 5-6, 2021.

Daniel Beckles, MD, PhD, FACS, Surgical Director Heart of Transplantation and MCS at Baylor Scott & White Health Central Texas, will present an on-demand lecture on the management of fluid overload with Aquadex™ ultrafiltration therapy. He will discuss the morbidity and mortality issues surrounding fluid overload in patients undergoing cardiac surgery, the cardio-renal connection, and how to best manage these patients. Dr. Beckles will share best practices and real-world experience on improving patient outcomes.

CHF Solutions will also have a virtual booth with live chat features to connect attendees directly to company representatives who can answer questions about the use of Aquadex SmartFlow® in cardiac surgery and critical care applications.

“Fluid overload is extremely common after cardiac procedures and can lead to ongoing cardio-renal complications. There’s work to be done in educating providers on best practices for effectively maintaining hemodynamic stability to prevent adverse outcomes,” said Nestor Jaramillo, Jr., President and CEO of CHF Solutions. “ERAS brings together some of the smartest and brightest experts from around the globe to incite collaboration to optimize outcomes, and we’re honored Daniel Beckles, MD, PhD, FACS is able to share his experience using Aquadex to improve how fluid overloaded patients are treated.”

Register to attend the 2021 ERAS Cardiac Society Virtual Conference by following this link.

About CHF Solutions CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

About the Aquadex SmartFlow System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the company’s activities around the ERAS Cardiac Society Virtual Conference. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS

INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
[e-mail]

Matt Bacso, CFA
Gilmartin Group LLC
[e-mail]

MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
[e-mail]